Pemetrexed is pyrrotopyrimidine-based, multi-targeted antifolate with broad in vivo antitumor activity. Originally identified as a highly efficient substrate for folylpolyglutamate synthase, pemetrexed potently inhibits multiple folate-dependent enzymes involved in both purine and pyrimidine synthesis including thymidylate synthase (K_i = 109 nM), dihydrofolate reductase (K_i = 7 nM), glycinamide ribonucleotide formyltransferase (K_i = 9.3 μM), and aminoimidazole carboxamide ribonucleotide formyltransferase (K_i = 3.6 μM).¹ Its antiproliferative activity has been demonstrated in a wide variety of solid tumors, including non-small cell lung, breast, mesothelioma, colorectal, pancreatic, gastric, bladder, cervix, and head and neck.^2,3

≥98%